PeptiDream Inc.
Notice of milestone fee receipt due to Phase 1 clinical trial initiation by Novartis
Receiving a milestone fee in connection with the Phase 1 clinical trial initiation under the collaboration with Novartis. Revenue recognition is planned for the third quarter of the fiscal year ending December 2026 (amount not disclosed). No impact on earnings guidance.
Key Figures
- Milestone fee receipt: amount unknown
- Recognition of revenue for Q3 FY2026: amount unknown
- In earnings guidance disclosed on Feb 16, 2026, already incorporated, no change
AI要約
Impact on performance and milestone revenue
We announced the receipt of a milestone fee associated with the Phase 1 clinical trial initiation under the joint research and development agreement with Novartis. Revenue is scheduled to be recognized in the third quarter of the fiscal year ending December 2026, with the amount not disclosed. The progress to this clinical stage underscores the strength of the collaboration and research capabilities. There is no change to existing earnings guidance.
Outlook and disclosure policy
This matter is expected to result in milestone revenue inflows aligned with clinical trial progress and has already been incorporated into the FY2026 earnings guidance. Since the amount is not disclosed at this time, additional information will be disclosed to investors in a timely manner when available.
PeptiDream Inc.
Company overview · Stock price · Financial data · All IR
